Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.
Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.
David Aggen, MD, PhD, reviews data from the CLEAR trial, which assessed the safety and efficacy of lenvatinib/pembrolizumab versus sunitinib.
Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.
Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.